Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ningxia Zhongke Biotechnology Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:600165'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -78.32 Med: -4.18 Max: 18.2
Current: -0.18
During the past 13 years, the highest Debt-to-EBITDA Ratio of Ningxia Zhongke Biotechnology Co was 18.20. The lowest was -78.32. And the median was -4.18.
SHSE:600165's Debt-to-EBITDA is ranked worse than 100% of 1268
companies
in the Chemicals industry
Industry Median: 2.005
vs SHSE:600165: -0.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ningxia Zhongke Biotechnology Co Debt-to-EBITDA Related Terms
Ningxia Zhongke Biotechnology Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningxia Zhongke Biotechnology Co Debt-to-EBITDA Chart
SHSE:600165 vs LIN, SHW, ECL: Debt-to-EBITDA Comparison
For the Specialty Chemicals subindustry, Ningxia Zhongke Biotechnology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ningxia Zhongke Biotechnology Co Debt-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Ningxia Zhongke Biotechnology Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ningxia Zhongke Biotechnology Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Ningxia Zhongke Biotechnology Co (SHSE:600165) has a Debt-to-EBITDA of -0.06 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ningxia Zhongke Biotechnology Co. According to the industry distribution chart, Ningxia Zhongke Biotechnology Co ranks #999999 out of 1268 companies in the Chemicals industry.
Is Ningxia Zhongke Biotechnology Co's Debt-to-EBITDA too high?
Ningxia Zhongke Biotechnology Co's current Debt-to-EBITDA is -0.06. Based on the distribution chart, Ningxia Zhongke Biotechnology Co ranks #999999 out of 1268 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Ningxia Zhongke Biotechnology Co has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningxia Zhongke Biotechnology Co's Debt-to-EBITDA compare to LIN and SHW?
According to the Chemicals industry distribution chart, Ningxia Zhongke Biotechnology Co ranks #999999 out of 1268 companies for Debt-to-EBITDA. This places Ningxia Zhongke Biotechnology Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Chemicals company?
The median Debt-to-EBITDA among Chemicals companies is 2.01, based on 1,268 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ningxia Zhongke Biotechnology Co. For the Chemicals industry, the median Debt-to-EBITDA is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningxia Zhongke Biotechnology Co's current Debt-to-EBITDA is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningxia Zhongke Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co (SHSE:600165) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥2.35, compared to a current price of ¥3.21 — trading 36.6% above its estimated fair value. The current Debt-to-EBITDA is -0.06. Ningxia Zhongke Biotechnology Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ningxia Zhongke Biotechnology Co (SHSE:600165), the current Debt-to-EBITDA is -0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningxia Zhongke Biotechnology Co (SHSE:600165) Overvalued in 2026?
Based on GuruFocus' analysis, Ningxia Zhongke Biotechnology Co stock appears to be overvalued.
The current stock price of ¥3.21 is trading 36.6% above its estimated GF Value™ of ¥2.35.
GuruFocus considers Ningxia Zhongke Biotechnology Co to be Significantly Overvalued.
Key valuation signals for SHSE:600165:
Debt-to-EBITDA: -0.06
GF Value™: ¥2.35 vs. price of ¥3.21 (36.6% above fair value)
No single metric tells the full story. See the SHSE:600165 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ningxia Zhongke Biotechnology Co Ltd is engaged in the production and sales of activated carbon products, preparation and storage of stem cells, trade and other businesses, as well as lauric acid.
47GF Score
Get the complete analysis for SHSE:600165
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600165 has been successfully added to your 
